The Center for Cell Reprogramming: Current 2020-2021 Series
All seminars will be held virtually until further notice
Wednesdays at 11:00am
(Unless otherwise noted)
October 28, 2020
Mingyao Ying, PhD
Title: Targeting Cancer Stem-like Cells for Brain Tumor Therapy
Dr. Ying focuses on developing more effective therapies for malignant brain tumors, including glioblastoma and medulloblastoma. He studies essential molecular mechanisms that support the self-renewal, tumorigenicity and therapeutic resistance of brain tumor stem-like cells. He further develops clinically translatable strategies to target these oncogenic mechanisms, based on drug repurposing.
Most recently, he uses human induced pluripotent stem cells to establish brain tumor models for drug discovery, and applies the synthetic mRNA technology for brain tumor therapy.
Associate Professor of Neurology
Hugo W. Moser Research Institute at Kennedy Krieger
Johns Hopkins University School of Medicine
November 18, 2020
Kandice Tanner, PhD
Dr. Tanner joined the National Cancer Institute as a Stadtman Tenure-Track Investigator in July, 2012, where she integrates concepts from molecular biophysics and cell biology to learn how cells and tissues sense and respond to their physical microenvironment, and to thereby design therapeutics and cellular biotechnology. She received tenure at NIH in 2020.
For her work, she has been awarded the 2013 National Cancer Institute Director’s Intramural Innovation Award, the 2015 NCI Leading Diversity award, Federal Technology Transfer Award in 2016 and 2018, the 2016 Young Fluorescence Investigator award from the Biophysical Society, and named as a Young Innovator in Cellular and Molecular Bioengineering in 2016 by the Biomedical Engineering Society.
Senior Investigator at Laboratory of Cell Biology
National Cancer Institute, NIH
December 9, 2020 at 1:00pm
Hani Goodarzi, PhD
Title: The RNA structural code underlying pathological regulation of RNA splicing in metastasis
Dr. Hani Goodarzi is an Assistant Professor at the University of California, San Francisco. With a dual background in computational and experimental genomics, he brings a multidisciplinary approach to studying human disease.
His research is focused on developing strategies that enable an unbiased search for previously unknown pathways that drive oncogenesis, metastasis, and neurodegeneration. By developing novel technologies for genome-wide measurement of hard-to-quantify RNA molecules, he has made key discoveries about the role of oncRNA, tRNAs, and tRNA fragments in cancer metastasis.
On the computational front, Dr. Goodarzi is focused on building network analytical models that help elucidate key pathways and processes that drive human disease. In 2017, for his contributions to cancer research, he was awarded the Martin and Rose Wachtel Award in Cancer Research and was recently named a Kimmel scholar. He was previously a recipient of the prestigious Blavatnik award for young scientists as well as the Tri-institutional Breakout prize.
Department of Biochemistry and Biophysics
University of California San Francisco
February 17, 2021
Keith Chan, PhD
Dr. Chan is a translational scientist who is excited about cancer research that expediates experimental therapies into clinical trials that can benefit cancer patient with focus on cancer stem-cells, tumoral heterogeneity, extracellular matrix, immune microenvironment, and cancer therapeutics
Dr. Chan received his PhD from the University of Texas, MD Anderson Cancer Center in 2004. He was trained under the classical concept that epithelial cancers develop via a multi-step process. Through pathologic evaluation of tumor tissues, he developed the appreciation that cancer is a disease of aberrant cellular differentiation. He then joined Prof. Irving Weissman’s laboratory at Stanford University to continue his postdoctoral studies (2004-09).
He was amongst the first to isolate cancer stem cells (CSCs) from human bladder urothelial carcinomas, and investigated CD47 as a mechanism for immune evasion. Dr. Chan is currently an associate professor at Baylor College of Medicine, emphasizing on translating CSC-targeted therapeutics into human clinical trials.
Department of Urology
Baylor College of Medicine
March 17, 2021
Salil Garg, MD, PhD
Dr. Garg’s lab focuses on the processes that generate heterogeneity in tumors and development and investigates the structures of genes and networks to understand how they contribute to variation and treatment failure in cancer.
Dr. Garg hails from Ohio and completed his B.S./M.S. at the University of Chicago. From there he completed doctoral work in immunobiology with Michael Brenner at Harvard Medical School before pursuing residency training in Pathology at Massachusetts General Hospital. Salil completed a postdoctoral fellowship with KI faculty member Phillip Sharp studying the contributions of microRNAs to heterogeneity. When he is not chasing difficult questions in the lab he engages in the even more difficult task of cheering for his hometown Cincinnati sports teams.
Koch Institute for Integrative Cancer Research
April 7, 2021
Jennifer Elisseeff, PhD
Dr. Elisseeff is an assistant professor in the Department of Biomedical Engineering at Johns Hopkins University. She cofounded Cartilix, Inc., a startup that translated adhesive and biomaterial technologies for treating orthopedic disease, acquired by Biomet Inc in 2009.
In 2009, she also founded Aegeria Soft Tissue and Tissue Repair, new startups focused on soft tissue regeneration and wound healing. She has published over 120 articles, book chapters and patent applications and given over 130 national and international invited lectures.
Her lab is working to understand fundamentals of the innate and adaptive immune responses to tissue damage and biomaterials in multiple model systems.
Assistant Professor of Biomedical Engineering
Johns Hopkins University
May 5, 2021
Ali Brivanlou, PhD
Dr. Brivanlou’s lab is focused on the molecular events and cellular interactions that regulate the emergence of key structures in the early embryo. The main focus is on the molecular basis of cell fate specification and pattering during early embryonic development.
Dr. Brivanlou received his doctoral degree in 1990 from the University of California, Berkeley. He joined Rockefeller in 1994 as assistant professor after postdoctoral work in Douglas Melton’s lab at Harvard University. Among his many awards are the Irma T. Hirschl/ Monique Weill-Caulier Trusts Career Scientist Award, the Searle Scholar Award, the James A. Shannon Director’s Award from the NIH and the Presidential Early Career Award for Scientists and Engineers
Stem Cell Biology and Molecular Embryology
*These seminars are for educational purposes and intended for the faculty, students and staff of Georgetown University.
In addition, these sessions are not recorded and closed to outside members of the public.
Past Speakers From Our Seminar Series
If you are interested in being a speaker at one of our Center for Cell Reprogramming Seminars, or if you have a topic you would like to hear please contact us here.